Takahashi Y, Deguchi T, Kuriyama M, Nakano M, Ueno K, Shinoda I, Takeda A, Itoh S, Doi T, Takeuchi T
Dept. of Urology, Gifu University School of Medicine.
Gan To Kagaku Ryoho. 1994 Sep;21(13):2311-4.
The clinical efficacy of intraarterial neoadjuvant chemotherapy with MTX, ADR and CDDP in 88 patients with advanced bladder cancer (> or = T2 or TCC G3) was evaluated. The intraarterial chemotherapy was performed using Seldinger's method. The three drugs were administered at the same time among 60 patients. In sixteen patients MTX was administered intravenously before intraarterial infusion of ADR and CDDP. In twelve patients, a high dose of CDDP (more than 100 mg/m2) was administered. The mean regression rate was 70%. That of the high-dose CDDP group was rather superior to the other two groups. However, the adverse reaction and duration of recovery were inferior to those of the other two groups. When intraarterial chemotherapy is performed as a neoadjuvant chemotherapy, care must be taken to determine the suitable dose.
评估了甲氨蝶呤（MTX）、阿霉素（ADR）和顺铂（CDDP）动脉内新辅助化疗对88例晚期膀胱癌（≥T2或TCC G3）患者的临床疗效。采用Seldinger法进行动脉内化疗。60例患者同时给予三种药物。16例患者在动脉内输注ADR和CDDP之前静脉注射MTX。12例患者给予高剂量顺铂（超过100mg/m²）。平均缓解率为70%。高剂量顺铂组的缓解率优于其他两组。然而，其不良反应和恢复时间劣于其他两组。当进行动脉内化疗作为新辅助化疗时，必须谨慎确定合适的剂量。
